MTOR and breast carcinoma: Meanwhile, enhanced IRE1 activity has been demonstrated to increase the production of protumorigenic cytokines in breast cancer cells to survive paclitaxel [51], and ATF6 is required to promote mTOR activation and STAT3 signaling to gain chemoresistance [52,53,54].